Condition: T-Cell Acute Lymphoblastic Leukemia/Lymphoma · Sponsor: Stephan Grupp MD PhD
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
This description comes directly from the study's public registry record.
Cell Therapy Intake Team · 445-942-5891 · CARTNurseNavigator@chop.edu
Melissa S Varghese, M.S. · 845-553-5358 · varghesem@chop.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06934382